Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:ALBONASDAQ:KMDANYSE:MNKNASDAQ:XENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsALBOAlbireo Pharma$44.15-0.2%$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsKMDAKamada$5.61+0.2%$5.91$4.08▼$6.53$322.41M1.0527,700 shs13,869 shsMNKMallinckrodt$0.12$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsXENEXenon Pharmaceuticals$43.05+0.1%$46.17$27.99▼$50.99$3.25B1.17373,975 shs364,266 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+60.08%ALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%KMDAKamada+0.18%-3.28%-12.34%-8.33%+22.81%MNKMallinckrodt0.00%0.00%0.00%0.00%-98.41%XENEXenon Pharmaceuticals+0.12%-0.92%-13.26%-6.53%+19.02%Your Money is Not Safe (Ad)Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOWMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALBOAlbireo PharmaN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.3329 of 5 stars3.55.00.00.02.61.73.1MNKMallinckrodtN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals3.4617 of 5 stars4.53.00.00.03.12.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.25Hold$17.50∞ UpsideALBOAlbireo PharmaN/AN/AN/AN/AKMDAKamada3.00Buy$11.0096.08% UpsideMNKMallinckrodtN/AN/AN/AN/AXENEXenon Pharmaceuticals3.00Buy$58.6736.28% UpsideCurrent Analyst RatingsLatest ALBO, AGLE, XENE, MNK, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/1/2024XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.003/1/2024XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.003/1/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $62.001/4/2024XENEXenon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.001/2/2024XENEXenon PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $56.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00ALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85KMDAKamada$142.52M2.26$0.43 per share13.13$4.25 per share1.32MNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/AXENEXenon Pharmaceuticals$9.43M344.35N/AN/A$14.18 per share3.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/AALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/AKMDAKamada$8.28M$0.1537.4013.68N/A5.81%5.66%3.57%5/22/2024 (Estimated)MNKMallinckrodtN/A-$116.19N/A∞N/A-82.59%20.32%2.49%N/AXENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)Latest ALBO, AGLE, XENE, MNK, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AALBOAlbireo PharmaN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59ALBOAlbireo PharmaN/A6.326.23KMDAKamadaN/A3.431.64MNKMallinckrodt1.180.570.31XENEXenon PharmaceuticalsN/A23.6523.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/AALBOAlbireo Pharma94.25%KMDAKamada20.38%MNKMallinckrodt83.74%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%ALBOAlbireo Pharma6.90%KMDAKamada36.10%MNKMallinckrodt0.30%XENEXenon Pharmaceuticals5.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableKMDAKamada37857.47 million36.73 millionOptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableALBO, AGLE, XENE, MNK, and KMDA HeadlinesSourceHeadlineXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analystsamericanbankingnews.com - March 22 at 1:28 AMXenon Pharmaceuticals Incmoney.usnews.com - March 21 at 10:13 AMInvestors Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)americanbankingnews.com - March 21 at 2:02 AMXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - March 19 at 8:26 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Wellington Management Group LLPmarketbeat.com - March 19 at 4:55 AMXENE Apr 2024 47.500 putfinance.yahoo.com - March 16 at 1:48 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Boosted by Walleye Capital LLCmarketbeat.com - March 15 at 5:21 AMXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 4:01 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Qube Research & Technologies Ltdmarketbeat.com - March 12 at 4:35 AMTimesSquare Capital Management LLC Has $20.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - March 11 at 9:49 AMInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stockinsidertrades.com - March 11 at 6:41 AMInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...finance.yahoo.com - March 9 at 12:06 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells $330,300.36 in Stockmarketbeat.com - March 8 at 7:33 PMAdage Capital Partners GP L.L.C. Sells 120,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - March 8 at 7:19 AMCantor Fitzgerald Weighs in on Xenon Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:XENE)marketbeat.com - March 7 at 7:23 AMXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 5 at 4:01 PMBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progressmarkets.businessinsider.com - March 5 at 10:33 AMXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 2:52 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:52 AMXenon Pharmaceuticals (NASDAQ:XENE) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPSmarketbeat.com - March 1 at 2:38 PMXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 2:30 PMRoyal Bank of Canada Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00marketbeat.com - March 1 at 11:21 AMBraidwell LP Has $71.85 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - March 1 at 10:17 AMXenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High Following Earnings Beatmarketbeat.com - March 1 at 10:14 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?Abercrombie & Fitch Stock Just Got an Upgrade to Beat Its PeersMarch 6, 2024 6:07 AMView Abercrombie & Fitch Stock Just Got an Upgrade to Beat Its PeersAll Headlines Company DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Albireo PharmaNASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.MallinckrodtNYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.